Review of Biologics in Children With Rheumatic Diseases

Shabina Habibi; Athimalaipet V Ramanan


Int J Clin Rheumatol. 2012;7(1):81-93. 

In This Article

Juvenile Systemic Lupus Erythematosus

Systemic lupus erythematosus in children is a more aggressive disease than in adults, having a higher frequency and severity of nephritis. There is a paucity of studies on the utility of biologics, especially B-lymphocyte depletion therapy in juvenile systemic lupus erythematosus. Retrospective series and case reports have reported efficacy of rituximab in children with aggressive disease not responding to conventional treatment.[80–83] Extrapolating from trials of adult lupus, drugs such as rituximab and belimumab show promise in treating manifestations of the disease not responding to conventional therapy.[84–87]


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: